Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oric Pharmaceuticals Inc.

9.24
-0.3900-4.05%
Volume:1.05M
Turnover:9.71M
Market Cap:787.42M
PE:-4.91
High:9.66
Open:9.64
Low:9.03
Close:9.63
52wk High:14.67
52wk Low:3.90
Shares:85.22M
Float Shares:55.46M
Volume Ratio:1.37
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8805
EPS(LYR):-1.8335
ROE:-48.45%
ROA:-30.87%
PB:3.58
PE(LYR):-5.04

Loading ...

Oric Pharmaceuticals announces preliminary efficacy, safety data from ORIC-944

TIPRANKS
·
May 29

Oric Pharmaceuticals announces $125M private placement

TIPRANKS
·
May 29

ORIC Pharmaceuticals Announces Promising Phase 1b Trial Results for ORIC-944 in Combination with AR Inhibitors in mCRPC Patients

Reuters
·
May 29

ORIC Pharmaceuticals Announces $125 Million Private Placement to Bolster Prostate Cancer Research and Development

Reuters
·
May 29

ORIC Pharmaceuticals: Promising Growth Potential with Superior Safety Profile and Strong Financial Position

TIPRANKS
·
May 27

Oric Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 09

Wedbush Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
May 06

Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating

MT Newswires Live
·
May 06

Oric Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

ORIC Pharmaceuticals Q1 EPS $(0.42) Beats $(0.51) Estimate

Benzinga
·
May 06

BRIEF-ORIC Pharmaceuticals Q1 Net Income USD -30.021 Million

Reuters
·
May 06

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 03

Oric Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

Reuters
·
May 02

BRIEF-ORIC Pharmaceuticals Presents Preclinical Data To Support The Potential Of Oric-944 As A Best-In-Class PRC2 Inhibitor For The Treatment Of Prostate Cancer

Reuters
·
Apr 29

Oric Pharmaceuticals presents preclinical ORIC-944 data at AACR

TIPRANKS
·
Apr 29

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire
·
Apr 29

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Apr 02

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Apr 01

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire
·
Mar 26